article thumbnail

COMP360 Psilocybin for Treatment-Resistant Depression: Positive Phase 3 Efficacy Data

Psychiatric Times

News Media Around the Practice Between the Lines PsychView Expert Perspectives Case-Based Psych Perspectives Clinical Case Collective Dialogues Payer-Provider Perspective Slideshows Videos Viewpoints Conferences Conference Coverage Conference Listing Publication Psychiatric Times Job Board CME/CE Partners Editorial Resources Clinical Consult Clinical (..)

article thumbnail

Exploring NMDA Antagonists for MDD

Psychiatric Times

FDA approval in 2022 for treating major depressive disorder was based on 3 pivotal clinical trails: - ASCEND 2 , in which it demonstrated separation from bupropion and rapid effects across 6 weeks - GEMINI, a phase 3 randomized, double-blind, placebo-conrolled trial in which it demonstrated a 16.6 May 19, 2022. January 21, 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score

Psychiatric Times

In 2022, a panel of TD experts developed a standardized tool that could be utilized easily in a clinical setting to assess TD’s impact on functioning in various domains. Spouses, partners, family, friends, and care providers can be imperative to capturing the full range of impairments. Goldberg, MD Stephen M. Goldberg, MD Stephen M.

article thumbnail

The 2025 Summer Heatwave: Implications for Patients With Psychiatric Disorders

Psychiatric Times

Newsletter Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients. Subscribe Now! Related Videos Related Content Advertisement June 13th 2025 Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score John J.

article thumbnail

How Do Psychiatry Residents Learn Psychopharmacology?

Psychiatric Times

link] Related Videos Related Content Advertisement May 29th 2025 Treatment Comparison: Somnolence/Sedation With Dopamine Partial Agonists vs D2 Receptor Antagonists Leah Kuntz April 9th 2022 Here's to a Psychedelic Revolution Amir Inamdar MBBS, DNB (Psych), MFPM May 23rd 2025 Looking Ahead to the ASCP Annual Meeting With Joseph F.

article thumbnail

Successfully Prescribing MAOIs for Depression

Psychiatric Times

Elsevier Academic Press; 2022:137-166. VA/DoD Clinical Practice Guideline: Management of Major Depressive Disorder. US Department of Veterans Affairs; 2022. 2022; 24;83(6):21m14267. Monoamine oxidase inhibitors for treatment-resistant depression. In: Quevedo J, Riva-Posse P, Bobo WV, eds. Curr Psychiatr. 2018;17(1)22-33.

article thumbnail

Using Serum Drug Levels

Psychiatric Times

Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. 2022:39(7):1,6-8. N Engl J Med. 1989;321(22):1489-1493. Guidelines. Accessed June 6, 2025. Psychiatric pharmacogenomics: the evidence base. Psychiatric Times. Serum levels of psychiatric drugs. Psychiatric Times. 2014;31(11):64-67.